Behçet's syndrome
- PMID: 12642292
- PMCID: PMC1771611
- DOI: 10.1136/bjo.87.4.381
Behçet's syndrome
Comment on
-
Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis.Br J Ophthalmol. 2003 Apr;87(4):423-31. doi: 10.1136/bjo.87.4.423. Br J Ophthalmol. 2003. PMID: 12642304 Free PMC article.
References
-
- Muhaya M, Lightman S, Ikeda E, et al. Behçet‘s disease in Japan and Great Britain. Ocular Immunol Inflam 2000;8:141–8. - PubMed
-
- Alpsoy E, Durusoy C, Yilmaz E, et al. Interferon alfa-2a in the treatment of Behçet‘s disease: a randomised, placeobo controlled and double-blind study. Arch Dermatol 2002;138:467–71. - PubMed
-
- Hasan A, Fortune F, Wilson K, et al. Role of γδ T cells in the pathogenesis and diagnosis of Behçet‘s disease. Lancet 1996;347:789–94. - PubMed
-
- Sfikakis PP, Theodossiadis PG, Katsiari CG, et al. Effect of infliximab on sight-threatening panuveitis in Behçet‘s disease. Lancet 2001;358:295–6. - PubMed
-
- Robertson LP, Hickling P. Treatment of recalcitrant orogenital ulceration of Behçet‘s syndrome with infliximab. Rheumatology 2001;40:473–4. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical